iCellate has 3 open roles within lab operations and IT - check it out.
iCellate, QIAGEN, and UKSH awarded Horizon2020 grant of €2,4 million for cancer innovation
Survival rate for pancreatic patients is low. Can ELEVATE offer a new treatment option?
Elthera AG, iCellate Medical AB, Targos GmbH and Prof. Dr. Susanne Sebens at the Institute of Experimental Cancer Research (IET) at the University of…
Stockholm, Sweden - 19 November 2020 - iCellate Medical has closed a successful round of financing, raising 26 MSEK from a combination of existing and…
A robust Clinical Team is critical for success
In the case of inherited cancer risk, the risk is inherited rather than the cancer itself.
Certain clinical questions may instead be answered with a minimally invasive alternative: the liquid biopsy.
iCellate is pleased to announce that we has been voted an organizational member of NACG, the Nordic Alliance for Clinical Genomics.
We now recruit for 3 new positions!
Come and join the iCellate team!
iCellate’s fast-paced and agile team is growing. We hope you’ll join us in revolutionizing cancer care.
Could genetic tests be useful tools to classify cancer in early stages, even before symptoms occur?
iCellate launches service to support oncologists in treatment selection for cancer patients.
Article by SvD 2019-09-04
We are looking for a new R&D Director
Welcome Bonoshree and Sofia!
New lab and office space in Hagalund